Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01974258 | Feb → Jul 2014 | neoplasm | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 1 | NCT02031731 | Jan → Apr 2014 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01897038 | Sep 2013 → Mar 2015 | hepatocellular carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01068977 | Aug 2007 → Jan 2010 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02044601 | Jun 2014 → Jun 2019 | lung cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 27 trials · 3 missed | ||||||
| Phase 2 | NCT01590719 | Jul 2012 → Oct 2014 | gastric cancer | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT01632228 | Jun 2012 → Jan 2016 | glioblastoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT01496742 | Apr 2012 → Nov 2015 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01519804 | Apr 2012 → Jan 2014 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01418222 | Sep 2011 → Mar 2013 | colorectal cancer | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT01186991 | Mar 2011 → Mar 2016 | breast cancer | Genentech, Inc. | Completed | Missed primary |
| Phase 2 | NCT00854308 | Apr 2009 → Nov 2010 | non-small cell lung carcinoma | Genentech, Inc. | Completed | Mixed |
| Phase 35 trials · 1 missed | ||||||
| Phase 3 | NCT02488330 | Aug 2015 → Jun 2018 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02031744 | Jan 2014 → Jan 2016 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01887886 | Dec 2013 → Feb 2015 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01662869 | Nov 2012 → Dec 2015 | gastric cancer | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT01456325 | Jan 2012 → Jan 2016 | non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Onartuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01456325 ↗ |
| Known as | MetMAb | “This randomized, Phase III, double-blind, placebo-controlled study will evaluate the safety and efficacy of MetMAb (onartuzumab) in combination with Tarceva (erlotinib)...” NCT02031744 ↗6“This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with...” NCT01590719 ↗ “A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy...” NCT01456325 ↗ “This phase I study will examine the pharmacokinetics and safety of Onartuzumab (MetMAb) in chinese patients with locally advanced or metastatic solid tumors.” NCT02031731 ↗ “MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.” NCT00854308 ↗ |
| Known as | PRO-143996 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743051 ↗ |
| Known as | PRO143966 | “A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally...” NCT01068977 ↗ |
| Known as | RO5490258 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01496742 ↗ |
| Action | Inhibit | “a monovalent antagonist antibody to the receptor MET” NCT00854308 ↗ |
| Modality | Monoclonal antibody | “a monovalent antagonist antibody to the receptor MET” NCT00854308 ↗ |
| Route | Intravenous | “15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.” NCT00854308 ↗ |
| Target | MET | “the receptor MET” NCT00854308 ↗ |